Tarsus Pharmaceuticals (TARS) Revenue (2021 - 2026)

Tarsus Pharmaceuticals' Revenue history runs 6 years deep, the most recent figure standing at $162.1 million for Q1 2026.

• In Q1 2026, Revenue rose 106.87% year-over-year to $162.1 million; the TTM figure through Mar 2026 stood at $535.1 million (up 128.99% YoY), while the FY2025 annual figure was $451.4 million, up 146.71% from the prior year.
• Revenue for Q1 2026 stood at $162.1 million, up from $151.7 million in the prior quarter.
• The five-year high for Revenue was $162.1 million in Q1 2026, with the low at $539000.0 in Q1 2022.
• The 5-year median for Revenue is $40.8 million (2024), against an average of $56.0 million.
• Peak annual rise in Revenue reached 2858.58% in 2022, while the deepest fall reached 98.39% in 2022.
• Tarsus Pharmaceuticals' Revenue stood at $10.0 million in 2022, then soared by 30.76% to $13.1 million in 2023, then soared by 407.86% to $66.4 million in 2024, then jumped by 128.39% to $151.7 million in 2025, then climbed by 6.85% to $162.1 million in 2026.
• Business Quant data shows TARS's Revenue at $162.1 million in Q1 2026, $151.7 million in Q4 2025, and $118.7 million in Q3 2025.